Table 3.
Relationship between the expression of CEBPA and the pathobiological characteristics of ovarian cancer patients [n (%)].
| Project | Total number of cases (n = 71) | CEBPA negative expression group (n = 22) | CEBPA positive expression group (n = 49) | χ2 value | P-value |
|---|---|---|---|---|---|
| Age | 0.280 | 0.596 | |||
| <50 years old | 29 | 10 (45.45%) | 19 (38.78%) | ||
| ≥50 years old | 42 | 12 (54.55%) | 30 (61.22%) | ||
| FIGO stage | 0.126 | 0.723 | |||
| I,II | 28 | 8 (36.36%) | 20 (40.82%) | ||
| III,IV | 43 | 14 (63.64%) | 29 (59.18%) | ||
| Histologic type | 1.656 | 0.647 | |||
| Serous cystadenocarcinoma | 32 | 10 (45.45%) | 22 (44.90%) | ||
| Mucosal cystadenocarcinoma | 11 | 5 (22.73%) | 6 (12.24%) | ||
| Endometrial carcinoma of ovary | 25 | 6 (27.27%) | 19 (38.78%) | ||
| Clear cell carcinoma | 3 | 1 (4.55%) | 2 (4.08%) | ||
| Degree of histological differentiation | 4.553 | 0.103 | |||
| Highly differentiated | 15 | 8 (36.36%) | 7 (14.29%) | ||
| Middle differentiation | 42 | 11 (50.00%) | 31 (63.27%) | ||
| Poorly differentiated | 14 | 3 (13.64%) | 11 (22.45%) | ||
| Lymph node metastasis | 0.006 | 0.937 | |||
| Without | 35 | 11 (50.00%) | 24 (48.98%) | ||
| With | 36 | 11 (50.00%) | 25 (51.02%) |
CEBPA, CCAAT enhancer-binding protein alpha.